Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages
Abstract
Neoadjuvant or perioperative chemoimmunotherapy has become a standard treatment option for selected patients with resectable non-small cell lung cancer (NSCLC), with eligibility determined by tumor stage, nodal involvement, oncogenic-driver status, regimen, and jurisdiction. Even so, most patients do not achieve a pathological complete response, and the determinants of resistance in early-stage disease remain incompletely understood. Tumor-associated macrophages are a key, and targetable, component of that resistance. We argue that abundance alone is an insufficient predictor of whether the myeloid compartment supports or suppresses a checkpoint-dependent response, and that macrophage state, namely the dominant subset, its spatial niche, and its trajectory under therapy, adds explanatory and therapeutic information whose weight remains to be established. Single-cell and spatial studies have identified metabolically distinct SPP1+, CCL18+, and oncofetal STAB1+ states associated with immunosuppressive niches in NSCLC, although these labels vary between datasets and their functional assignments are provisional. Limited serial neoadjuvant data from a single cohort suggest that treatment expands tissue-resident macrophages and shifts tumor-associated macrophages toward a neutral rather than antitumor phenotype, most evidently in tumors that reached a major pathological response. Current agents, including CSF1R and CD47–SIRPα blockade, TREM2, LILRB2 and PI3Kγ inhibitors, and chimeric antigen receptor (CAR) macrophages, act on programs that cut across these subsets rather than on the subsets themselves, and almost all efficacy evidence derives from advanced or preclinical disease. The resectable, biomarker-rich perioperative window is nonetheless the most informative setting in which to test subset-informed myeloid reprogramming.
Related
- Spatiotemporal remodeling of the tumor–immune interface during neoadjuvant immunotherapy for oral squamous cell carcinoma: pathological response, resistance, and dynamic biomarkers
- Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity
- Butyrate reverts Chlamydia pneumoniae -induced transcriptional suppression of macrophage polarization markers and promotes chlamydial clearance in macrophages
- Precision targeting of tumor-associated macrophages via a 6-substituted pyrrolo[2,3-d]pyrimidine chimeric molecule for enhanced cancer immunotherapy
- CAR-macrophage immunotherapy targeting fibroblast-like synoviocytes ameliorates inflammatory and degenerative arthritis
BibTeX
@article{li2026macrophage,
title = {{Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages}},
author = {Hang Li and Bingqiang Li and Zhongkun Li and Zhe Wang and Wenjuan Sun and Kunpeng Yang and Yunlong Yang and Bao Wang},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1956181},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1956181},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages
AU - Hang Li
AU - Bingqiang Li
AU - Zhongkun Li
AU - Zhe Wang
AU - Wenjuan Sun
AU - Kunpeng Yang
AU - Yunlong Yang
AU - Bao Wang
PY - 2026
DA - 2026/11/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1956181
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1956181
AB - Neoadjuvant or perioperative chemoimmunotherapy has become a standard treatment option for selected patients with resectable non-small cell lung cancer (NSCLC), with eligibility determined by tumor stage, nodal involvement, oncogenic-driver status, regimen, and jurisdiction. Even so, most patients do not achieve a pathological complete response, and the determinants of resistance in early-stage disease remain incompletely understood. Tumor-associated macrophages are a key, and targetable, component of that resistance. We argue that abundance alone is an insufficient predictor of whether the myeloid compartment supports or suppresses a checkpoint-dependent response, and that macrophage state, namely the dominant subset, its spatial niche, and its trajectory under therapy, adds explanatory and therapeutic information whose weight remains to be established. Single-cell and spatial studies have identified metabolically distinct SPP1+, CCL18+, and oncofetal STAB1+ states associated with immunosuppressive niches in NSCLC, although these labels vary between datasets and their functional assignments are provisional. Limited serial neoadjuvant data from a single cohort suggest that treatment expands tissue-resident macrophages and shifts tumor-associated macrophages toward a neutral rather than antitumor phenotype, most evidently in tumors that reached a major pathological response. Current agents, including CSF1R and CD47–SIRPα blockade, TREM2, LILRB2 and PI3Kγ inhibitors, and chimeric antigen receptor (CAR) macrophages, act on programs that cut across these subsets rather than on the subsets themselves, and almost all efficacy evidence derives from advanced or preclinical disease. The resectable, biomarker-rich perioperative window is nonetheless the most informative setting in which to test subset-informed myeloid reprogramming.
SN - 1664-3224
ER -